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Summary 
 
In this review, we examine 131I treatment options 
available to patients.  Research has shown that 
Graves’ Disease patients who undergo 131I 
treatment are cured of hyperthyroidism but have 
the chance to develop hypothyroidism, depending 
on the dosage used (4-5).   The two different 
treatment options are high dose (8-14.6 mCi) 
treatment, and low dose (2 mCi) 131I treatment.  
Data from previous studies were collected from 
patients who had been diagnosed with Graves’ 
Disease and treated with 131I.  The data shows that 
low dose treatment results in a higher likelihood of 
euthyroidism.  Based on the data, low dose 131I 
treatment is a better option for patients that do not 
have heart related complications due to Graves’ 
Disease. 
             
Introduction 
 
History of Graves’ Disease 
Graves’ Disease is an autoimmune disease in which 
the body produces antibodies that stimulate the thyroid, 
causing it to produce excess amounts of 
triiodothyronine (T3) and thyroxine (T4) (1).  The 
disease was recognized by Dr. Robert J. Graves in the 
1830s, and is the most common cause of 
hyperthyroidism in the United States today (1).  
Research has also found that the disease runs in 
families and appears to be genetic, although Grave’s 
Disease does occur in patients with no family history. 
(2).  Some studies have found a connection between 
human leukocyte antigen and the onset of Graves’ 
Disease; however, the complete cause remains 
unknown (1).   
 
Typical Patient Profile 
Graves’ Disease most commonly affects Caucasian 
women, aged 45-65 (1).  After the disease appears, 
symptoms include anxiety, difficulty sleeping, fatigue, 
frequent bowel movements, weight loss, and heat 
sensitivity (1-2).  Visual symptoms include goiter 
(enlarged thyroid gland) and the thickening and 
reddening of the skin (1-2).  Graves’ Disease patients 
also exhibit a phenomenon called Graves’ 
ophthalmopathy, which is manifested as bulging of the 
eyes (1-2).  This is caused by an immune response in 
which the body attacks eye muscles, causing the 
tissues to swell (3). 
____________________________________________ 
 
*These authors wrote the paper for Biology 138: Endocrine Diseases, 
taught by Dr. Nicole Sleiter.  
 
Normal Physiology of Hypothalamic-Pituitary-Thyroid 
Axis Compared to Graves’ Disease Physiology 
The hypothalamic-pituitary-thyroid axis involves the 
release of four main hormones: thyroid releasing 
hormone (TRH), thyroid stimulating hormone (TSH), T3 
and T4 (3).  Normally, the hypothalamus releases TRH, 
which in turn stimulates the pituitary to release TSH (3).  
TSH then binds to receptors on the thyroid causing the 
gland to release T3 and T4 (3).  An important 
component to T3 and T4 is iodine; the thyroid is the 
only organ in the body that absorbs this element (3).  In 
Graves’ Disease, the body produces antibodies that 
bind to the TSH receptors on the thyroid gland.  The 
binding of these antibodies mimics the binding of TSH, 
thus causing the release of T3 and T4 (3).  Excess 
amounts of free T3 and T4 are what cause 
hyperthyroidism (3).  T3 and T4 also regulate body 
metabolism, which is what explains certain symptoms, 
such as weight loss, increased sensitivity to heat, and 
anxiety (3).   
 
Treatment Options For Graves’ Disease Patients 
Several options are available to treat Graves’ Disease.  
The most common and non- invasive treatment 
involves oral antithyroid (ATD) drugs, such as Tapazole 
(1).  These drugs lower the amount of hormone 
produced by the thyroid gland (1).  Beta-blockers are 
also given to the patient to treat symptoms, such as 
increased heart rate (1-2).   Beta-blockers function by 
blocking the effects of epinephrine and norepinephrine 
on -adrenergic receptors, decreasing heart rate (3).  A 
second treatment option is surgery to remove the 
thyroid gland (1).  Removal of the thyroid removes the 
source of T3 and T4, and thus relieves symptoms (2).  
However, this treatment can also lead to 
hypothyroidism because the thyroid is no longer 
producing any T3 or T4 (2).  Partial thyroidectomy is 
another option, as it removes only part of the thyroid 
and decreases the likelihood of hypothyroidism (2).  A 
third and more recent treatment of the disease involves 
use of radioactive iodine (1-2).  When the thyroid 
absorbs radioactive iodine, the radiation kills off thyroid 
cells, shrinking the number of cells that release T3 and 
T4 (1).  Typically, Iodine 131 (131I) in millicurie (mCi) 
amounts is used in this procedure (4).  There is some 
criticism of this method, as excess 131I can destroy too 
much thyroid tissue causing a shift into hypothyroidism 
(1).  We have researched treatment options, and 
hypothesize that low dose 131I treatment for people 
with Graves’ Disease is the most effective way to return 
normal thyroid function, or euthyroidism. 
 
Two Schools of Thought Involving Radioiodine 
Treatment 
There are currently two different approaches to treating 
Graves’ disease involving the use of 
131
I.  The first 
approach involves a large dosage of the radioactive 
iodine (8-14.6 mCi), which quickly destroys almost all of 
the thyroid tissue (4).  An advantage to high dose 
131
I 
treatment is that the subjects quickly leave a 
hyperthyroid state (4).  Figure 1 illustrates the success 
rate of high dose 
131
I treatment in curing 
hyperthyroidism.  The radiation kills a very large portion 
of the thyroid, leaving the treated patient without the 
ability to maintain a euthyroid state.  One drawback to 
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Figure 1. Percent of subjects that remain hyperthyroid after 
various dosages of Iodine-131 (Alexander and Larsen, 2002). 
 
this method is that patients who undergo high dosage 
radioiodine treatment almost always end up in a 
hypothyroid state afterwards (4).  One study found that 
83% of 225 patients became hypothyroid after the 
treatment (4).   
The second 
131
I method used to treat Graves’ disease is 
low dose therapy.  This method involves lower dosages 
of radioiodine (2 mCi) to achieve an eventual euthyroid 
state (5).  The lower dose of 
131
I destroyed the thyroid 
at a much slower rate than high dosages, resulting in a 
period of time where the patient was euthyroid.  Figure 
2 indicates that as time went on, more patients became 
euthyroid and, after 2 years 75% were euthyroid.  
However, in one study that followed subjects treated 
with low dose 
131
I treatment, almost all the subjects 
became hypothyroid after a number of years (5).  This 
study also found that the yearly incidence of 
hypothyroidism was 4-6% per year (5).  It is likely that 
the 
131
I remains in the thyroid for many years after 
treatment, continually destroying thyroid tissue and thus 
potentially resulting in hypothyroidism. 
 
Effect of ATD on Radioiodine Treatment 
The effect of ATDs on radioiodine treatment 
is an important component in insuring successful 
outcome.  Figure 3 indicates that patients who took 
ATDs for more than 4 months before 
131
I treatment had 
an increased treatment failure rate.  This failure rate is 
 
Figure 2. Percent of patients and time it took for them to 
become euthyroid after low dose therapy (Hoskin et al., 1985). 
  
thought to be due to the radioresistance caused by 
ATDs (6).  Some ATDs, such as Propylthiouracil (PTU), 
function by inhibiting the enzyme thyroperoxidase (7).  
When inhibited, the enzyme cannot add iodine to 
thyroglobulin, the precursor of T4 (7).  When given 
before 
131
I treatment drugs, including PTU, increase 
failure rate because they block the radioactive iodine 
from becoming part of the hormone and thus prevent 
the radiation from destroying tissue (7). 
 
 
 
Figure 3. Failure rate of High Dose Iodine-131 treatment on 
patients who previously took ATD drugs for different lengths of 
time (Cooper, 1994). 
 
The Best Treatment Options 
Our findings indicate that, in the majority of patients 
with hyperthyroidism caused by Graves’ Disease, the 
most beneficial treatment is a multiple low dose 
131
I 
program.  After undergoing high dose treatment, onset 
of hypothyroidism is virtually assured with almost no 
euthyroid period (4).  After hypothyroidism occurs, the 
patient must be on thyroid hormone replacement 
therapy for the rest of their life (5).  Multiple low doses 
are less likely to cause hypothyroidism than the higher 
doses, and patients who undergo low dose 
131
I 
treatment are more likely to experience a euthyroid 
period (4-5).  The length of this period varies, but we 
believe that because there is only a chance for patients 
to shift into a hypothyroid state after low dose 
treatment, this is the better option.  Despite this, there 
are some advantages to high dosages.  The rapid shift 
from hyperthyroidism to hypothyroidism is beneficial if 
the patient has cardiac complications because it 
removes the strain on the heart faster than low dose 
treatment (4).  Patients who undergo 
131
I treatment 
should also not take ATDs before treatment, as they 
cause a higher failure rate due to decreased iodine 
uptake (4). 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication 
and should be cited as such only with the consent of 
the author. 
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